Form 4: Olema Pharmaceuticals Executive Granted Stock Options

Shane William Charles Kovacs, Chief Operating and Financial Officer of Olema Pharmaceuticals, was granted stock options to purchase 320,000 shares of common stock.

Summary

• On February 28, 2025, Shane William Charles Kovacs, the Chief Operating and Financial Officer of Olema Pharmaceuticals, Inc., was granted stock options.
• The options allow Kovacs to purchase 320,000 shares of Olema Pharmaceuticals' common stock at an exercise price of $4.37 per share.
• The options vest over time, with 25% vesting on February 28, 2026, and the remaining 75% vesting monthly over the subsequent 36 months, contingent upon Kovacs' continued service.
• The options expire on February 27, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the executive and the company's future.

Positives

• The granting of stock options to a key executive like the CFO can be seen as a positive incentive for them to remain with the company and work towards its success.
• The vesting schedule aligns the executive's interests with the long-term performance of the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock options are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical industry, often benchmarked against peer companies of similar size and stage of development.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typically determined based on factors such as the executive's role, performance, and the company's overall compensation strategy.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CFO to drive company performance.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates